[Contrast density and side effect rate in lumbar myelography--a clinical comparison of Meglumin-Iocarmate and Metrizamide].
The author reports that side effects were somewhat more frequent after metrizamide than after meglumin-iocarmate, in the course of a comparative study carried out at the reporting hospital from the beginning of 1977, using the water-soluble x-ray contrast media Amipaque (metrizamide) and Dimer X (meglumin-iocarmate).
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007482:Iothalamate Meglumine / Q000009:adverse effects*; D008297:Male; D008793:Metrizamide / Q000009:adverse effects*; D009192:Myelography / Q000009:adverse effects*; D013118:Spinal Cord Diseases / Q000000981:diagnostic imaging
D008793:Metrizamide; D007482:Iothalamate Meglumine
Kontrastdichte und Nebenwirkungsrate bei lumbaler Myelographie--klinischer Vergleich von Meglumin-locarmat und Metrizamid.